Teru Hideshima

Dr. Teru Hideshima


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
THTeru Hideshima
Teru Hideshima
PRPaul G. Richardson
Paul G. Richardson
KAKenneth Anderson
Kenneth Anderson
Novel agents, including the proteasome inhibitor bortezomib, have significantly improved the response and survival of patients with multiple myeloma over the last decade. Despite these advances, many patients relapse or do not benefit from the currently available therapies; thus, multiple myeloma remains an incurable disease. Deacetylase inhibitors (DACi), including panobinostat and vorinostat, have recently emerged as novel agents being evaluated in the treatment of multiple myeloma. Deacetylases are a group of enzymes with effects on various intracellular proteins, including histones, transcription factors, and molecular chaperones. Although DACi inhibit cell growth and induce apoptosis in multiple myeloma cells as a single agent, synergistic activity has been observed when they were used in combination with bortezomib. The mechanistic basis of synergy is multifactorial and includes disruption of protein degradation and inhibition of the interaction of multiple myeloma cells with the tumor microenvironment. This review summarizes recent advancements in the understanding of the mechanism of action of proteasome inhibitors and DACi in multiple myeloma and examines the biological basis of their synergistic effects. Data from the studies summarized here have been used as the rationale for the implementation of phase II and III clinical trials of DACi, alone and combined with bortezomib, in relapsed and refractory multiple myeloma. Mol Cancer Ther; 10(11); 2034–42. ©2011 AACR.

1 September 2002
Verified
Journal Article
Closed access
RLRichard LeBlanc
Richard LeBlanc
LCLaurence P Catley
Laurence P Catley
THTeru Hideshima
Teru Hideshima
SLSuzanne Lentzsch
Suzanne Lentzsch
CMConstantine Mitsiades
Constantine Mitsiades
KAKenneth C Anderson
Kenneth C Anderson

1 January 2003
Verified
Journal Article
Closed access
MAMasaharu Akiyama
Masaharu Akiyama
THTeru Hideshima
Teru Hideshima
THToshiaki Hayashi
Toshiaki Hayashi
YTYu-Tzu Tai
Yu-Tzu Tai
CMConstantine Mitsiades
Constantine Mitsiades
KAKenneth C Anderson
Kenneth C Anderson

8 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
THTeru Hideshima
Teru Hideshima
KAKenneth Anderson
Kenneth Anderson
The multiple myeloma (MM) bone marrow (BM) microenvironment consists of different types of accessory cells. Both soluble factors (i.e., cytokines) secreted from these cells and adhesion of MM cells to these cells play crucial roles in activation of intracellular signaling pathways mediating MM cell growth, survival, migration, and drug resistance. Importantly, there is crosstalk between the signaling pathways, increasing the complexity of signal transduction networks in MM cells in the BM microenvironment, highlighting the requirement for combination treatment strategies to blocking multiple signaling pathways.


1 October 2003
Verified
Journal Article
Closed access
DCDharminder Chauhan
Dharminder Chauhan
GLGuilan Li
Guilan Li
RSReshma Shringarpure
Reshma Shringarpure
Klaus PodarKlaus Podar
Klaus Podar
YOYasuyuki Ohtake
Yasuyuki Ohtake
KAKenneth C Anderson
Kenneth C Anderson